Skip to main content
Log in

Differences in Attitudes, Knowledge and Use of Economic Evaluations in Decision-Making in The Netherlands

The Dutch Results from the EUROMET Project

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Abstract

Objective: To investigate differences in attitudes, knowledge and actual use of economic evaluations in different groups of decision-makers, and to compare the results from the Netherlands with the overall European results of the European Network on Methodology and Application of Economic Evaluation Techniques (EUROMET) project.

Design and setting: Members of the EUROMET group conducted interviews and surveys with politicians, regulators, hospital pharmacists and physicians in The Netherlands. Three approaches of investigation could be adopted: (i) a postal questionnaire survey, (ii) semi-structured interviews, and (iii) a focus-group approach.

Main outcome measures and results: In the Netherlands, decision-makers generally have a positive attitude towards economic evaluations. Nevertheless, their actual use and knowledge of economic evaluations are still limited. Hospital pharmacists and regulators are more objective than physicians and politicians, who also base their judgements on other societal values. Hospital pharmacists and regulators have a greater knowledge of economic evaluations, and they use them more often than the other groups. Most decision-makers do not want to base their decisions strictly on a cost-effectiveness ranking alone. Our findings were similar to the findings in other European countries.

Conclusions: Decision-makers prefer to make their own broad comparisons of advantages and disadvantages, and do not base their decisions solely on a single summary measure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I
Fig. 1
Fig. 2
Table II

Similar content being viewed by others

References

  1. Eddy DM. Clinical decision making: from theory to practice. What do we do about costs? JAMA 1990; 264: 1161, 1165, 1169–70

    Google Scholar 

  2. OECD Health Data 1998 [CD-ROM]. Organisation for Economic Co-operation and Development (OECD), 1998

  3. Williams A. Cost-effectiveness analysis: is it ethical? J Med Ethics 1992; 18: 7–11

    Article  PubMed  CAS  Google Scholar 

  4. Alban A. Economic appraisal: what is the use? Presented at the Third Nordic Health Economists’ Study Group. Available from the Danish Hospital Institute, Copenhagen

  5. Alban A. The role of economic appraisal in Denmark. Soc Sci Med 1994; 38: 1647–52

    Article  PubMed  CAS  Google Scholar 

  6. Davies L, Coyle D, Drummond M. Current status of economic appraisal of health technology in the european community: report of the network. The EC network on the methodology of economic appraisal of health technology. Soc Sci Med 1994; 38: 1601–7

    Article  PubMed  CAS  Google Scholar 

  7. Drummond M, Cooke J, Walley T. Economic evaluation under managed competition: evidence from the UK. Soc Sci Med 1997; 45: 583–95

    Article  PubMed  CAS  Google Scholar 

  8. Duthie T, Trueman P, Chancellor J, et al. Research into the use of health economics in decision making in the United Kingdom, phase II: is health economics ’for good or evil’? Health Policy 1999; 46: 143–57

    Article  PubMed  CAS  Google Scholar 

  9. Elsinga E, Rutten FF. Economic evaluation in support of national health policy: the case of The Netherlands. Soc SciMed 1997; 45: 605–20

    CAS  Google Scholar 

  10. Von der Schulenburg JM. The influence of economic evaluation studies on health care decision-making — a European survey. Amsterdam: IOS Press, 2000

    Google Scholar 

  11. National Organisation for Quality Assurance in Hospitals (CBO). Treatment and prevention of coronary heart disease through lowering serum cholesterol levels. Utrecht: National Organisation for Quality Assurance in Hospitals (CBO), 1998: 86

    Google Scholar 

  12. Eddy DM. Clinical decision making: from theory to practice. Cost-effectiveness analysis: a conversation with my father. JAMA 1992; 267: 1669–75

    Article  PubMed  CAS  Google Scholar 

  13. Menzel P, Gold MR, Nord E, et al. Toward a broader view of values in cost-effectiveness analysis of health. Hastings Cent Rep 1999; 29: 7–15

    PubMed  CAS  Google Scholar 

  14. Nord E, Pinto JL, Richardson J, et al. Incorporating societal concerns for fairness in numerical valuations of health programmes. Health Econ 1999; 8: 25–39

    Article  PubMed  CAS  Google Scholar 

  15. Mosteller F, Ware JE, Levine S. Finale panel: comments on the conference on advances in health status assessment. Med Care 1989; 27: S282–94

    Article  Google Scholar 

  16. Anonymous. Netherlands to have pharmacoeconomic guidelinesScrip 1999 Apr 23; 2431: 6

    Google Scholar 

Download references

Acknowledgements

The research for this article was supported by the EU-Biomed II project (European Network on Methodology and Application of Economic Evaluation Techniques) [project number BMH4-CT96-1666].

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jeannette E. F. Zwart-van Rijkom.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rijkom, J.E.F.Zv., Leufkens, H.G.M., Busschbach, J.J.V. et al. Differences in Attitudes, Knowledge and Use of Economic Evaluations in Decision-Making in The Netherlands. Pharmacoeconomics 18, 149–160 (2000). https://doi.org/10.2165/00019053-200018020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-200018020-00005

Keywords

Navigation